ICON plc (ICLR) PT Raised to $154 at Mizuho Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
ICON plc (ICLR) Buys MolecularMD Corporation
February 21, 2019 10:03 AM ESTMolecularMD Corporation, a molecular diagnostic specialty laboratory that enables the development and commercialisation of precision medicines in oncology, announced today that it has been acquired by ICON plc (NASDAQ: ICLR). MolecularMDs extensive scientific and clinical biomarker experience expands ICONs capabilities in molecular diagnostic testing and also adds expanded testing platforms, including next-generation sequencing and immunohistochemistry, to ICONs laboratory service offering. MolecularMDs specialty central laboratory offering and associated client base extends ICONs reach into the support of precision... More
ICON plc (ICLR) Tops Q4 EPS by 3c, Reaffirms Guidance
February 20, 2019 4:32 PM ESTICON plc (NASDAQ: ICLR) reported Q4 EPS of $1.63, $0.03 better than the analyst estimate of $1.60. Revenue for the quarter came in at $679 million versus the consensus estimate of $675.88 million.
2019 outlook reaffirmed with revenue guidance in the range of $2,735 - $2,835 million and earnings per... More